The results showed that hypoxia, inflammatory, TNFα, IL-6/STAT3, and IL-2/STAT5 enrichments of CD8+ T cells might contribute to PD-1or PD-L1 treatment resistance in NSCLC (Fig. 3B–F). Here, IL6 is linked to non-small cell lung carcinoma.